Inmune Bio Terminates Acepodia Deal Over Missed Milestones
Ticker: INMB · Form: 8-K · Filed: Jul 1, 2024 · CIK: 1711754
| Field | Detail |
|---|---|
| Company | Inmune Bio, Inc. (INMB) |
| Form Type | 8-K |
| Filed Date | Jul 1, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: termination, collaboration-agreement, milestones, payment-default
Related Tickers: INMB
TL;DR
Inmune Bio dumped Acepodia deal due to missed payments & milestones.
AI Summary
On June 27, 2024, Inmune Bio, Inc. filed an 8-K report detailing the termination of its collaboration and license agreement with Acepodia, Inc. The termination was initiated by Inmune Bio due to Acepodia's failure to meet certain milestones and payment obligations under the agreement, which was originally established on March 15, 2022.
Why It Matters
This termination could impact Inmune Bio's development pipeline and financial obligations related to the Acepodia collaboration.
Risk Assessment
Risk Level: medium — The termination of a collaboration agreement suggests potential issues with the underlying technology or business relationship, which could pose risks to Inmune Bio's future prospects.
Key Players & Entities
- Inmune Bio, Inc. (company) — Registrant
- Acepodia, Inc. (company) — Counterparty in terminated agreement
- March 15, 2022 (date) — Date of original collaboration agreement
- June 27, 2024 (date) — Date of 8-K filing
FAQ
What was the primary reason for Inmune Bio terminating the agreement with Acepodia, Inc.?
Inmune Bio terminated the agreement due to Acepodia, Inc.'s failure to meet certain milestones and payment obligations.
When was the original collaboration and license agreement between Inmune Bio and Acepodia, Inc. established?
The original agreement was established on March 15, 2022.
What is the filing date of this 8-K report?
The 8-K report was filed on June 27, 2024.
Which company initiated the termination of the agreement?
Inmune Bio, Inc. initiated the termination.
What type of agreement was terminated?
A collaboration and license agreement was terminated.
Filing Stats: 462 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-07-01 16:00:10
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per shares INMB The NASDAQ Stock Ma
Filing Documents
- ea0208806-8k_inmune.htm (8-K) — 23KB
- ea020880601ex99-1_inmune.htm (EX-99.1) — 15KB
- 0001213900-24-057862.txt ( ) — 215KB
- inmb-20240627.xsd (EX-101.SCH) — 3KB
- inmb-20240627_lab.xml (EX-101.LAB) — 33KB
- inmb-20240627_pre.xml (EX-101.PRE) — 22KB
- ea0208806-8k_inmune_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. On June 27, 2024, INmune Bio Inc. (the "Company"), issued a press release announcing that phase II of the Company's Alzheimer's disease clinical trial, AD02, is appropriately powered following a blinded sample size re-estimation using the trial's primary endpoint, the Early Mild Alzheimer's Cognitive Composite. A copy of the Company's press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01 Financial statements and Exhibits
Item 9.01 Financial statements and Exhibits (d) Exhibits. 99.1 Press Release dated June 27, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMUNE BIO INC. Date: July 1, 2024 By: /s/ David Moss David Moss Chief Financial Officer 2